The FDA wants these cold medicines off the shelves. Should Canada follow?
The FDA has proposed removing phenylephrine, a common ingredient in decongestants, due to its ineffectiveness, which may ...
FDA seeks to remove ingredient from cold medicines after data shows it does not work
The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...
PharmiWeb1d
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults ...
Five Common Drugs You Should Avoid Using While Breastfeeding
Around 92% of people living in the UK have used at least one over-the-counter drug in the past year. While these drugs make ...
Health on MSN6d
FDA Plans to Ban Ineffective Cold Medicine Ingredient—How It Will Affect You
The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...
CNET on MSN4d
Which Decongestants Are Effective? Why the FDA Wants to Pull a Popular Medicine Ingredient
Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...
Pharmabiz2d
ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions
ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...
The American Journal of Managed Care8h
Deaths Due to Opioid Overdose Fall for the 12th Consecutive Month
Opioid overdose deaths have decreased for 12 months, with 70,655 predicted deaths through June 2024, down from 86,401 in June ...
ALK Licenses Rights To Neffy®, The First Approved Adrenaline Nasal Spray For Emergency Treatment Of Allergic Reactions (Anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, <a target= ...
manilatimes1d
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...
ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® (Nasdaq: MIST) today reported financial results for the ...